New Products and Industry News
New negative pressure wound technology released
Vital Needs International (VNI, San Antonio, Tex.) announced the release of a wound care technology, “The Voyager,” that is designed to close wounds by supporting negative pressure therapy techniques related to plastic and reconstructive surgery.
According to the company, the system is smaller, transportable, generates less noise than other negative pressure technology on the market, and may improve patient quality of life.
The product is lightweight and about the size of a deck of cards.
The technology has applications for patients with chronic and traumatic wounds related to diabetes, and/or have had procedures related to general and plastic surgery, such as burns, biopsies and reconstructive surgery. The system can be used in the hospital, extended care facilities, and the home.
For more information, visit www.vitalneeds.com.
Ointment helps reduce scarring
Triple B Ointment (Triple B Ointment Inc., Roswell, MN) was formulated more than 25 years ago by pharmacist Robert Bell. He is still manufacturing the ointment today. The product helps promote healing and reduce scarring. The ointment works quickly and easily to initiate the body’s natural healing process and help reduce scarring.
The ointment contains zinc oxide, starch, Peruvian balsam, ichthamnol, thymol, camphor, menthol, and phenol in a base of white petroleum jelly. The ointment is sold over the counter for general use.
For a free sample, visit www.triplebointment.com/sample.htm.
Diabetic foot ulcer study initiated
KeraCure, Inc. (Chicago, Ill.) announced that the first patients have been treated in a pilot study to test its investigational device, KeraPac™. The company plans to enroll up to 15 patients with Stage III and Stage IV diabetic foot ulcers. The company recently received Food and Drug Administration (FDA) approval to conduct the study in a single center at the General Clinical Research Center at the University of Michigan in Ann Arbor, Mich. The company expects to complete enrollment early in 2005.
The device is comprised of human keratinocytes, grown on microcarrier beads and packaged in a unique patented dressing configuration. The product is placed externally on a clean wound and removed several days later. It is distinguished by its simplicity, low cost to produce, and storage capability.
For more information, please call (312) 780-7438.
Medicare to reimburse for electromagnetic therapy
Ivivi Technologies (Northvale, NJ) developer of the SofPulse, a pulsed electromagnetic therapy medical device, announced that the US Centers for Medicare and Medicaid Services (CMS) will reimburse for PMF therapy for chronic Stage III or Stage IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers. Now, long-term rehab centers, hospitals, nursing homes, and doctors can get reimbursed for patients treated with this therapy.
The device painlessly and effectively emits an extremely low-power radio frequency signal into a desired area, directly through dressings, casts, or clothing, without touching the skin.
For more information, visit www.ivivitechnologies.com.
